Objective: To retrospectively analyze the impact of primary
PGF on CMV
pneumonia in patients who have undergone haplo-HSCT. Methods: The clinical data of 122 patients who underwent haplo-HSCT at the Peking University Institute of Hematology from 2011-2012 were retrospectively reviewed. The incidence rate of CMV
pneumonia between
PGF and good graft function (GGF) was compared, and the factors were analyzed. In addition, outcomes in
PGF patients with CMV
pneumonia have been described. Results: Total 122 patients were retrospectively reviewed, and of these, 26 (21.3% ) had
PGF, while 96 (78.7% ) had GGF. In addition, 15 patients had CMV
pneumonia, and the median time to the development of CMV
pneumonia was 103 (31-262) days; the 1-year cumulative incidence of CMV
pneumonia was 12.3% (95% CI 6.2% -18.4% ) . In patients with primary
PGF and GGF after Haplo-HSCT, the incidence of CMV
pneumonia was 30.8% (8/26) and 7.3% (7/96) , respectively (P=0.002) . Moreover, 24 patients had CMV
viremia (92.3% ) , while of the 96 GGF patients, 79 (82.3% ) had CMV
viremia (P=0.212) . In multivariate analysis, the results showed that primary
PGF had a significant influence on CMV
pneumonia (P=0.005) . Compared with those without CMV
pneumonia, patients with CMV
pneumonia had poorer overall survival 37.3% (95% CI 11.2% -63.4% ) vs. 78.9% (95% CI 72.0% -87.6% ) (χ(2)=16.361, P<0.001) . The 1-year overall survival (OS) was 25.0% (95% CI 0% -55.0% ) and 50.0% (95% CI 26.9% -73.1% ) (χ(2)=4.656, P=0.031) in
PGF patients with (8/26) and without (18/26) CMV
pneumonia. Conclusion: The incidence of cytomegalovirus
pneumonia in patients with primary poor graft function increases and the survival rate decreases.